Nobiletin downregulates the SKP2-p21/p27-CDK2 axis to inhibit tumor progression and shows synergistic effects with palbociclib on renal cell carcinoma.

Tingting ChenLiu LiuYonghong ZouXiaoyan HuWenfeng ZhangTao ZhouXi LuoWeihua Fu Jie Xu

Published in: Cancer biology & medicine (2021)

Nobiletin downregulated the SKP2-p21/p27-CDK2 axis to inhibit tumor progression and showed synergistic tumor inhibition effects with the CDK4/6 inhibitor, palbociclib, on RCC, which indicates a potential new therapeutic strategy.

Keyphrases

renal cell carcinoma
cell cycle
poor prognosis
metastatic breast cancer
cell proliferation
climate change